Compare FDMT & CCIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDMT | CCIX |
|---|---|---|
| Founded | 2013 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.6M | 395.2M |
| IPO Year | 2019 | N/A |
| Metric | FDMT | CCIX |
|---|---|---|
| Price | $8.82 | $10.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $31.71 | N/A |
| AVG Volume (30 Days) | ★ 609.1K | 21.5K |
| Earning Date | 05-08-2026 | 11-07-2013 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | N/A |
| P/E Ratio | ★ N/A | $45.59 |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $3.68 | $10.46 |
| 52 Week High | $12.34 | $11.32 |
| Indicator | FDMT | CCIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 58.28 |
| Support Level | $8.39 | $10.58 |
| Resistance Level | $8.80 | $10.83 |
| Average True Range (ATR) | 0.65 | 0.05 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 15.87 | 79.78 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Churchill Capital Corp IX is a blank check company.